CLSA Raises INNOVENT BIO TP to HKD139.9, Secures Another Partnership DealAASTOCKS News·Jul 15 at 11:36 PM01801-0.39%SPRO-0.84%
Innovent licenses IBI355 rights to Spero for up to $1.1bnPharmaceutical Technology·Jul 15 at 04:01 AM01801-0.39%SPRO-0.84%
Spero Therapeutics inks major CD40L and royalty dealsTip Ranks·Jul 15 at 03:11 AMSPRO-0.84%01801-0.39%
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L AntibodyPR Newswire·Jul 14 at 05:00 AMSPRO-0.84%01801-0.39%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Jul 14 at 12:05 PMGALT-2.59%CARL+6.02%
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties | SPRO Stock NewsStockTitan·Jul 13 at 09:02 PMSPRO-0.84%KKR+2.28%
